Recent FDA approvals provide physicians the opportunity to initiate long-acting injectable (LAI) antipsychotics in acute settings, but there is limited research comparing the efficacy an...
BACKGROUND: Significant delay can occur between the first dose of a long-acting injectable (LAI) antipsychotic and achievement of efficacious plasma concentrations, which is usually addre...
OASIS was an observational study that evaluated real-world outcomes of atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Overall, CGI-S scores at basel...
Objective: Evaluate efficacy and safety of a 2-month dose of aripiprazole lauroxil (AL) with a 1-day initiation regimen during hospitalization for an acute exacerbation of schizophrenia.
...
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida.
Background: A survey was carried out to investigate the relative importance of an...